Choose Your Country or Region

Syk

Choose Selective Syk Inhibitors

Syk Signaling Pathway Map

Syk Products

All (20)
Syk Inhibitors (20)
New Syk Products

Catalog No.	Product Name	Information	Product Use Citations
S0871^New	Gusacitinib (ASN-002)	Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S1533	R406 (free base)	R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 (free base) triggers apoptosis. Phase 1.	Theranostics, 2022, 12(5):2232-2247 Free Radic Biol Med, 2022, S0891-5849(22)00004-1 J Virol, 2022, e0020022
S2194	R406	R406 is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 induces apoptosis. Phase 1.	Theranostics, 2022, 12(5):2232-2247 Free Radic Biol Med, 2022, S0891-5849(22)00004-1 J Virol, 2022, e0020022
S2206	Fostamatinib (R788) disodium	Fostamatinib disodium (R788, Tamatinib Fosdium), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.	Int J Hematol, 2022, 10.1007/s12185-021-03220-9 J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9 Haematologica, 2020, 15;haematol2019241729
S2625	Fostamatinib (R788)	Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.	Hum Cell, 2022, 10.1007/s13577-022-00671-y Int J Hematol, 2022, 10.1007/s12185-021-03220-9 Hum Cell, 2021, 34(6):1911-1918
S3026	Piceatannol	Piceatannol, a natural stilbene, is a selective Syk inhibitor and ~10-fold selectivity versus Lyn.	Front Immunol, 2021, 12:766178 Front Vet Sci, 2021, 8:606197 Clin Transl Med, 2021, 11(2):e339
S3226	Dehydroabietic acid	Dehydroabietic acid (DAA, DHAA), a naturally occurring diterpene resin acid derived from coniferous plants such as Pinus and Picea, displays anti-inflammatory activity via suppression of Src-, Syk-, and TAK1-mediated pathways.
S3566^New	Cerdulatinib (PRT062070)	Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
S4921	MNS (3,4-Methylenedioxy-β-nitrostyrene)	MNS is a tyrosine kinase inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.	J Biomol Struct Dyn, 2019, 10.1080/07391102.2019.1640133 Phytomedicine, 2019, 61:152859 Toxicol Res (Camb), 2016, 5(1):188-196
S4944	Fostamatinib disodium hexahydrate	Fostamatinib (R788) disodium (Tamatinib Fosdium) hexahydrate, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay.	Int J Hematol, 2022, 10.1007/s12185-021-03220-9 J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9 ScholarsArchive@OSU, 2020, None
S6519	R112	R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor with Ki value of 96 nM.
S7006	BAY-61-3606	BAY-61-3606 is a potent and selective inhibitor of Syk kinase (Ki = 7.5 nM). BAY-61-3606 induces cell cycle arrest and apoptosis.	JCI Insight, 2021, e149376 Biomed Res, 2021, 42(2):53-66 Nat Cell Biol, 2019, 21(6):778-790
S7286	RO9021	RO9021 potently inhibits SYK kinase activity with an average IC50 of 5.6 nM and suppresses B-cell receptor signaling.
S7523	Entospletinib (GS-9973)	Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM in a cell-free assay and showed 13- to >1000-fold cellular selectivity for Syk over other kinases(including Jak2, ckit, Flt3, Ret, KDR) as assessed by target protein phosphorylation or functional response.	Cancer Res, 2022, canres.0218.2021 Theranostics, 2022, 12(5):2232-2247 Hum Cell, 2022, 10.1007/s13577-022-00671-y
S7634	Cerdulatinib (PRT062070) hydrochloride	Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.	Hum Cell, 2022, 10.1007/s13577-022-00671-y Cancer Lett, 2021, 512:28-37 Mol Carcinog, 2021, 60(7):481-496
S7738	PRT-060318 2HCl	PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase with an IC50 of 4 nM, as an approach to HIT treatment.	PLoS Pathog, 2022, 18(4):e1010468 FASEB J, 2020, 34(11):15208-15221 Cell Commun Signal, 2019, 17(1):122
S8032	PRT062607 (P505-15) HCl	PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.	Mol Cell, 2021, S1097-2765(21)00264-1 Sci Signal, 2021, 14(682)eabc1648 Biochem Pharmacol, 2021, S0006-2952(21)00185-4
S8442	TAK-659	TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent toward both SYK and FLT3.	Am J Physiol Cell Physiol, 2021, 320(5):C902-C915 ScholarsArchive@OSU, 2020, 51 ScholarsArchive@OSU, 2020, None
S8948	SRX3207	SRX3207 is an orally active dual inhibitor of Syk-PI3K with IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM for Syk, Zap70, BRD41, BRD42, PI3K alpha, PI3K delta, PI3K gamma, respectively. SRX3207 blocks tumor immunosuppression and increases anti-tumor immunity.
S9715	Lanraplenib (GS-9876)	Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
S0871^New	Gusacitinib (ASN-002)	Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S1533	R406 (free base)	R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 (free base) triggers apoptosis. Phase 1.	Theranostics, 2022, 12(5):2232-2247 Free Radic Biol Med, 2022, S0891-5849(22)00004-1 J Virol, 2022, e0020022
S2194	R406	R406 is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 induces apoptosis. Phase 1.	Theranostics, 2022, 12(5):2232-2247 Free Radic Biol Med, 2022, S0891-5849(22)00004-1 J Virol, 2022, e0020022
S2206	Fostamatinib (R788) disodium	Fostamatinib disodium (R788, Tamatinib Fosdium), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.	Int J Hematol, 2022, 10.1007/s12185-021-03220-9 J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9 Haematologica, 2020, 15;haematol2019241729
S2625	Fostamatinib (R788)	Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.	Hum Cell, 2022, 10.1007/s13577-022-00671-y Int J Hematol, 2022, 10.1007/s12185-021-03220-9 Hum Cell, 2021, 34(6):1911-1918
S3026	Piceatannol	Piceatannol, a natural stilbene, is a selective Syk inhibitor and ~10-fold selectivity versus Lyn.	Front Immunol, 2021, 12:766178 Front Vet Sci, 2021, 8:606197 Clin Transl Med, 2021, 11(2):e339
S3226	Dehydroabietic acid	Dehydroabietic acid (DAA, DHAA), a naturally occurring diterpene resin acid derived from coniferous plants such as Pinus and Picea, displays anti-inflammatory activity via suppression of Src-, Syk-, and TAK1-mediated pathways.
S3566^New	Cerdulatinib (PRT062070)	Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
S4921	MNS (3,4-Methylenedioxy-β-nitrostyrene)	MNS is a tyrosine kinase inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.	J Biomol Struct Dyn, 2019, 10.1080/07391102.2019.1640133 Phytomedicine, 2019, 61:152859 Toxicol Res (Camb), 2016, 5(1):188-196
S4944	Fostamatinib disodium hexahydrate	Fostamatinib (R788) disodium (Tamatinib Fosdium) hexahydrate, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay.	Int J Hematol, 2022, 10.1007/s12185-021-03220-9 J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9 ScholarsArchive@OSU, 2020, None
S6519	R112	R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor with Ki value of 96 nM.
S7006	BAY-61-3606	BAY-61-3606 is a potent and selective inhibitor of Syk kinase (Ki = 7.5 nM). BAY-61-3606 induces cell cycle arrest and apoptosis.	JCI Insight, 2021, e149376 Biomed Res, 2021, 42(2):53-66 Nat Cell Biol, 2019, 21(6):778-790
S7286	RO9021	RO9021 potently inhibits SYK kinase activity with an average IC50 of 5.6 nM and suppresses B-cell receptor signaling.
S7523	Entospletinib (GS-9973)	Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM in a cell-free assay and showed 13- to >1000-fold cellular selectivity for Syk over other kinases(including Jak2, ckit, Flt3, Ret, KDR) as assessed by target protein phosphorylation or functional response.	Cancer Res, 2022, canres.0218.2021 Theranostics, 2022, 12(5):2232-2247 Hum Cell, 2022, 10.1007/s13577-022-00671-y
S7634	Cerdulatinib (PRT062070) hydrochloride	Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.	Hum Cell, 2022, 10.1007/s13577-022-00671-y Cancer Lett, 2021, 512:28-37 Mol Carcinog, 2021, 60(7):481-496
S7738	PRT-060318 2HCl	PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase with an IC50 of 4 nM, as an approach to HIT treatment.	PLoS Pathog, 2022, 18(4):e1010468 FASEB J, 2020, 34(11):15208-15221 Cell Commun Signal, 2019, 17(1):122
S8032	PRT062607 (P505-15) HCl	PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.	Mol Cell, 2021, S1097-2765(21)00264-1 Sci Signal, 2021, 14(682)eabc1648 Biochem Pharmacol, 2021, S0006-2952(21)00185-4
S8442	TAK-659	TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent toward both SYK and FLT3.	Am J Physiol Cell Physiol, 2021, 320(5):C902-C915 ScholarsArchive@OSU, 2020, 51 ScholarsArchive@OSU, 2020, None
S8948	SRX3207	SRX3207 is an orally active dual inhibitor of Syk-PI3K with IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM for Syk, Zap70, BRD41, BRD42, PI3K alpha, PI3K delta, PI3K gamma, respectively. SRX3207 blocks tumor immunosuppression and increases anti-tumor immunity.
S9715	Lanraplenib (GS-9876)	Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
S0871^New	Gusacitinib (ASN-002)	Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S3566^New	Cerdulatinib (PRT062070)	Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.